Welcome to Screening Hub – your partner in the next generation of drug discovery. Our AI-powered platform accelerates the journey from research to market, making the drug development process faster, more precise, and cost-effective.
Traditional drug development can take years, delaying critical treatments. Our AI solution speeds up the process, getting innovations to market faster.
Developing new drugs is expensive, often costing millions. Our platform reduces these costs by streamlining processes and enhancing efficiency.
Early-stage decisions are risky and can lead to costly setbacks. Our AI minimizes these risks with precise data analysis, boosting your chances of success.
Users upload their raw data from screening processes or experimental results into the platform.
The platform’s AI algorithms analyze the data, identifying key patterns and potential candidates for drug development.
The platform generates intuitive visualizations, allowing researchers to easily interpret the results and make informed decisions.
Based on the analysis, the platform provides actionable recommendations, enabling you to prioritize the most promising candidates for further development.
Representation of cell proportions for different wells of the same treatment
Representation of cell proportions for different wells of the same treatment
Automated Cell Screening
Details: We perform cell screening for your compounds with speed, efficiency, and a high degree of automation.
Technology: High-Content Screening (HCS) using a modern Cell Painting approach. This includes six dyes to stain eight cellular components and organelles (nucleus, endoplasmic reticulum, nucleoli and RNA, F-actin cytoskeleton, Golgi, plasma membrane, and mitochondria), allowing for detailed cellular morphology analysis and the detection of subtle phenotypic changes.
Example Application: Immunology
Cells: Macrophages (M0, M1, M2, Dead Cells)
Reference: Leading German pharmaceutical company, Pasteur Institute Paris
Integrated Cell Screening with Sequencing Data
Details: We combine microscopy-based high-throughput screening (HTS) with transcriptomic data using multimodal clustering. This integration enables the identification of drug hits without the need for genetic manipulation of cells, while also providing transcriptomic insights without generating additional data.
Example Application: Oncology
Cells: Cancer Cells, Osteosarcoma Cells
Reference: Aimed Analytics, ZIM Funding Program
Screening of 3D Data Without Information Loss
Details: Using a hybrid methodology, this module processes 3D data such as tissue sections by combining 3D Convolutional Neural Networks (3D-CNNs) with other techniques like Graph Neural Networks (GNNs). This allows for detailed analysis of complex 3D structures and cellular interactions.
Example Application: Dermatology, Skin Aging, Skin Diseases
Cells: Skin Cells + Cannabinoids
Reference: Fraunhofer IGB, 420 Pharma, ZIM/Eureka
Optimizing Biopharmaceutical Production
Details: This AI-based solution identifies high-producer single cells and provides (semi-)quantitative insights into the cells‘ production capacity. This significantly shortens biopharmaceutical production timelines and reduces material costs.
Example Application: Biopharmaceuticals
Cells: High-Producer Cells, Production Cell Lines
Reference: Fraunhofer IGB
ScreeningHub utilizes an advanced deep learning platform specifically designed for image processing and analysis, offering highly accurate predictions and analyses that surpass traditional methods.